Cargando…

Current evidence on the use of anakinra in COVID-19

Despite the progressing knowledge in COVID-19 management, remdesivir is the only agent that got approval to inhibit viral replication. However, there are limited data about effective immunomodulatory agents to prevent cytokine release in COVID-19. Cytokine release syndrome in COVID-19 resembles seco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khani, Elnaz, Shahrabi, Marzieh, Rezaei, Haleh, Pourkarim, Fariba, Afsharirad, Hoda, Solduzian, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296834/ https://www.ncbi.nlm.nih.gov/pubmed/35905562 http://dx.doi.org/10.1016/j.intimp.2022.109075

Ejemplares similares

Thromboprophylaxis for Coagulopathy Related to COVID-19 in Pediatrics: A Narrative Review
por: Sahrai, Hadi, et al.
Publicado: (2023)

Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021)

Anakinra for patients with COVID-19
por: Maoujoud, Omar, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Valette, Xavier, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Martin-Silva, Nicolas, et al.
Publicado: (2020)

Effect of anakinra in COVID-19
por: Kooistra, Emma J, et al.
Publicado: (2020)

Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview
por: Rezaee, Haleh, et al.
Publicado: (2021)

Anakinra for severe forms of COVID-19
por: Laine, Marc, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19
por: Khan, Naim Akhtar
Publicado: (2020)

Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series
por: Clark, Kristina E N, et al.
Publicado: (2020)

Anakinra: a silver lining in COVID-19?
por: Gupta, Rahul
Publicado: (2020)

Anakinra for patients with COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Effect of anakinra in COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Cytokine storm and use of anakinra in a patient with COVID-19
por: Nemchand, Priyanka, et al.
Publicado: (2020)

Use of anakinra in severe COVID-19: A case report
por: Filocamo, Giovanni, et al.
Publicado: (2020)

Anakinra in COVID-19: A step closer to the cure
por: Barkas, Fotios, et al.
Publicado: (2022)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Anakinra for severe forms of COVID-19 – Authors' reply
por: Hayem, Gilles, et al.
Publicado: (2020)

Anakinra in COVID-19: important considerations for clinical trials
por: King, Andrew, et al.
Publicado: (2020)

EMA assessing safety of anakinra in adults with COVID-19
Publicado: (2021)

Anakinra for the prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2023)

Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()
por: Muñoz-Jiménez, Alejandro, et al.
Publicado: (2021)

Relationship of Blood Group with Level of Cooperation of Pediatric Dental Patients
por: Heidari, Alireza, et al.
Publicado: (2022)

Anakinra for severe forms of COVID-19: a cohort study
por: Huet, Thomas, et al.
Publicado: (2020)

Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic
por: Della Paolera, Sara, et al.
Publicado: (2021)

Jaundice in a patient treated with Anakinra in a context of Covid-19
por: Tarhini, H., et al.
Publicado: (2021)

Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report
por: Karadeniz, Hazan, et al.
Publicado: (2020)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

An open label trial of anakinra to prevent respiratory failure in COVID-19
por: Kyriazopoulou, Evdoxia, et al.
Publicado: (2021)

Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19 †
por: García-García, José A, et al.
Publicado: (2021)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Anakinra: Jaundice: case report
Publicado: (2021)

Continuous IV infusion of anakinra
por: Saunders, Brittney N., et al.
Publicado: (2023)

Rapid Response to Cytokine Storm Inhibition Using Anakinra in a Patient With COVID-19 Myocarditis
por: Trpkov, Cvetan, et al.
Publicado: (2020)

A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19
por: Kharazmi, Amir Behnam, et al.
Publicado: (2021)

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis
por: Dimopoulos, George, et al.
Publicado: (2020)

Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis
por: Dahms, Karolina, et al.
Publicado: (2023)

Tocilizumab versus anakinra in COVID-19: results from propensity score matching
por: Arcani, Robin, et al.
Publicado: (2023)

Evaluation of the effects of anakinra treatment on clinic and laboratory results in patients with COVID-19
por: Siyer, Ozge, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3ivscmcnmu1t8fsucl37p9udmt